RU2003123101A - Изолированные молекулы, включающие эпитопы, содержащие сульфатированные остатки, антитела для эпитопов и их использование - Google Patents

Изолированные молекулы, включающие эпитопы, содержащие сульфатированные остатки, антитела для эпитопов и их использование Download PDF

Info

Publication number
RU2003123101A
RU2003123101A RU2003123101/13A RU2003123101A RU2003123101A RU 2003123101 A RU2003123101 A RU 2003123101A RU 2003123101/13 A RU2003123101/13 A RU 2003123101/13A RU 2003123101 A RU2003123101 A RU 2003123101A RU 2003123101 A RU2003123101 A RU 2003123101A
Authority
RU
Russia
Prior art keywords
antibody
binding fragment
complex
agent
antigen binding
Prior art date
Application number
RU2003123101/13A
Other languages
English (en)
Russian (ru)
Inventor
Жанет ЛАЗАРОВИЦ (IL)
Жанет ЛАЗАРОВИЦ
Йошевед ХАГАЙ (IL)
Йошевед ХАГАЙ
Даниэль ПЛАКСИН (IL)
Даниэль ПЛАКСИН
Тиква ВОГЕЛ (IL)
Тиква ВОГЕЛ
Абрахам НИМРОД (IL)
Абрахам НИМРОД
Хаит МАР-ХАИМ (IL)
Хаит МАР-ХАИМ
Эстер ЗАНТОН (IL)
Эстер ЗАНТОН
Тамар РИХТЕР (IL)
Тамар РИХТЕР
Боаз АМИТ (IL)
Боаз АМИТ
Лена КУПЕРМАН (IL)
Лена КУПЕРМАН
Тувиа ПЕРЕЦ (IL)
Тувиа ПЕРЕЦ
Авигдор ЛЕВАНОН (IL)
Авигдор ЛЕВАНОН
Original Assignee
Сейвиент Фармасьютикэлс, Инк. (Us)
Сейвиент Фармасьютикэлс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сейвиент Фармасьютикэлс, Инк. (Us), Сейвиент Фармасьютикэлс, Инк. filed Critical Сейвиент Фармасьютикэлс, Инк. (Us)
Publication of RU2003123101A publication Critical patent/RU2003123101A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2003123101/13A 2000-12-29 2001-12-31 Изолированные молекулы, включающие эпитопы, содержащие сульфатированные остатки, антитела для эпитопов и их использование RU2003123101A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25894800P 2000-12-29 2000-12-29
US75118100A 2000-12-29 2000-12-29
US09/751,181 2000-12-29
US60/258,948 2000-12-29

Publications (1)

Publication Number Publication Date
RU2003123101A true RU2003123101A (ru) 2005-03-10

Family

ID=26946974

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003123101/13A RU2003123101A (ru) 2000-12-29 2001-12-31 Изолированные молекулы, включающие эпитопы, содержащие сульфатированные остатки, антитела для эпитопов и их использование

Country Status (13)

Country Link
EP (1) EP1406930A4 (enExample)
JP (1) JP2005503756A (enExample)
KR (1) KR20030091953A (enExample)
CN (1) CN100347194C (enExample)
BR (1) BR0116764A (enExample)
CA (1) CA2433225A1 (enExample)
CZ (1) CZ20031982A3 (enExample)
HU (1) HUP0700079A2 (enExample)
IL (1) IL156689A0 (enExample)
MX (1) MXPA03005945A (enExample)
PL (1) PL366223A1 (enExample)
RU (1) RU2003123101A (enExample)
WO (1) WO2002053700A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
RU2005101622A (ru) * 2002-07-01 2006-01-27 Савиент Фармасьютикалс, Инк (Us) Композиции и способы терапевтического лечения
CA2531283A1 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
BRPI0411945A (pt) * 2003-06-30 2006-10-24 Bio Technology General Israel Anticorpos e seus usos
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
ES2655833T3 (es) * 2004-05-11 2018-02-21 AbGenomics Coöperatief U.A. Epítopos que inducen la muerte de células T
EP2637672B1 (en) 2010-11-12 2018-08-22 Gentium S.r.l. Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
ES2660969T5 (es) 2012-06-22 2021-09-03 Gentium S R L Método basado en euglobulina para determinar la actividad biológica de defibrotida
WO2016013828A1 (ko) * 2014-07-21 2016-01-28 연세대학교 산학협력단 황산화된 더피 케모카인 수용체의 세포 외 도메인 1 변이체 및 이의 용도
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
WO2019027034A1 (ja) * 2017-08-04 2019-02-07 公立大学法人福島県立医科大学 新規ポリペプチド及びその用途
CN109929036B (zh) * 2017-12-19 2024-12-03 泰州迈博太科药业有限公司 一种表位特异的抗体筛选方法及所筛选到的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011778A1 (en) * 1991-12-12 1993-06-24 The Scripps Research Institute Bifunctional antithrombotic molecules and antithrombotic polypeptides
CZ401497A3 (cs) * 1995-06-14 1998-07-15 The General Hospital Corporation P-selektinové ligandy a příbuzné molekuly a způsoby
KR100523506B1 (en) * 1995-08-03 2005-10-24 Peptide and O-glycan inhibitors of selectin mediated inflammation
US5985833A (en) * 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
JP2002518354A (ja) * 1998-06-16 2002-06-25 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ 糖硫酸ペプチド、その合成方法および使用方法

Also Published As

Publication number Publication date
HUP0700079A2 (en) 2007-05-02
WO2002053700A2 (en) 2002-07-11
JP2005503756A (ja) 2005-02-10
CN1649900A (zh) 2005-08-03
PL366223A1 (en) 2005-01-24
CA2433225A1 (en) 2002-07-11
BR0116764A (pt) 2007-01-09
MXPA03005945A (es) 2004-10-15
WO2002053700A3 (en) 2004-02-12
EP1406930A4 (en) 2007-01-10
KR20030091953A (ko) 2003-12-03
CN100347194C (zh) 2007-11-07
IL156689A0 (en) 2004-01-04
EP1406930A2 (en) 2004-04-14
CZ20031982A3 (cs) 2004-09-15

Similar Documents

Publication Publication Date Title
RU2003123101A (ru) Изолированные молекулы, включающие эпитопы, содержащие сульфатированные остатки, антитела для эпитопов и их использование
JP7354079B2 (ja) 尿路の新生物の治療における使用のための多重特異性抗体
US7829064B2 (en) Anti-CD74 immunoconjugates and methods
US20090220486A1 (en) Antibodies and uses thereof
US11746156B2 (en) Antibody therapeutics that bind CD123
US20100092455A1 (en) Novel anti-proliferation antibodies
CA2979219A1 (en) Antibody therapeutics that bind psma
US20040202665A1 (en) Compositions and methods for therapeutic treatment
US6652853B2 (en) Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
RU2005101621A (ru) Антитела и их применения
MXPA05000271A (es) Composiciones y metodos para tratamiento terapeutico.
US20080274100A1 (en) Antibodies and uses thereof
CA2531283A1 (en) Specific human antibodies
WO2018233333A1 (zh) 一种靶向人肿瘤干细胞的单克隆抗体及其应用
US20040208877A1 (en) Antibodies and uses thereof
ES2541907T3 (es) Secuencias de nucleótidos y proteínas de un anticuerpo dirigido frente a un epítopo común para ferritínas humanas ácidas y básicas, anticuerpos monoclonales o moléculas semejantes a anticuerpo que comprenden estas secuencias y uso de éstos.
WO2026056990A1 (zh) 抗体药物偶联物联合vegfr tki和/或蒽环类药物治疗癌症的用途
Stigbrand et al. Targeting tumours with radiolabeled antibodies
Hamblett Optimization of pretargeted radioimmunotherapy
Ménard et al. Production and clinical application of the MOv18 monoclonal antibody
Tibben Diagnostic and therapeutic targeting of ovarian cancer using monoclonal antibodies
KR20140054723A (ko) 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20080416